Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational
drug called IMGS-001 and to determine how well it can work in treating patients with advanced
solid tumors that have come back or are not improving after receiving other drugs that are
commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different
doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or
spread to other parts of the body following treatment with other available therapies will be
treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to
further determine the safety and potential effectiveness in select cancer types.